Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm

• Status: Completed
• Trial end date: 2019-10-09
• Target enrollment: 0
• Participant gender: All

Summary

The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Swiss Tropical & Public Health Institute
• Collaborator: Public Health Laboratory Ivo de Carneri
• Treatments: DMP 777; Mebendazole; Piperazine; Piperazine citrate

Criteria

Inclusion Criteria:

• Male or female children aged between 3 and 12 years;

• Written informed consent signed by caregiver;

• Was examined by a study physician before treatment;

• Provided two stool samples at baseline;

• Hookworm EPG > 100 and at least two Kato-Katz thick smears slides with more than one hookworm egg;

Exclusion Criteria:

• Pregnant;

• Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, such as can upon initial clinical assessment;

• Suffers from severe anemia (Hb < 80 g/l);

• Received anthelminthic treatment or metronidazole within past four weeks.

• Attending other clinical trials during the study.